Clinical Trial Detail

NCT ID NCT02880345
Title RADVAX: A Trial of Combined Pembrolizumab and Hypofractionated Radiation in Patients With Advanced Urothelial Cancer Who Have Progressed on Anti-PD-1/PD-L1 Monotherapy
Recruitment Withdrawn
Gender both
Phase Phase 0
Variant Requirements No
Sponsors Abramson Cancer Center of the University of Pennsylvania
Indications

transitional cell carcinoma

Therapies

Pembrolizumab

Age Groups: adult senior

No variant requirements are available.